FDA Drug Center Reorganization Needs Approps Committee Approval

The future of FDA's proposed reorganization of its Office of New Drugs is unclear, as Congress must approve the agency's proposal before it can move forward. But the committees have yet to receive a detailed briefing from FDA, a Senate committee aide told Inside Health Policy . On June 4, FDA Commissioner Scott Gottlieb and drug center Director Janet Woodcock touted the agency's plans, which Gottlieb has highlighted in previous speeches, and shed light on more details about what the...